The Food and Drug Administration has issued a new warning for the use of Botox with cerebral palsy patients.
The new warning is an update to the 2008 safety warning issued by the FDA. This warning will now be added to the product label and patient information of all Botox products. The FDA said that the use of Botox in pediatric cerebral palsy and birth injury patients was never approved. It was also never approved to help those experiencing cerebral palsy symptoms such as spastic muscles.
Although the FDA had previously given the warning, Botox has recently become a widely accepted form of treatment for cerebral palsy patients. This form of treatment is often used at pediatric and orthopedic clinics around the country.
The new research provided by the FDA shows that the amount of botulinum toxin found in Botox can have drastic side effects on children. These side effects can include difficulty breathing, muscular weakness, drooping eyelids, speech disorder, difficulty swallowing, double vision and facial drooping. The FDA requests that all signs of these side effects should be reported to MedWatch.
